Effect of phenylbutazone administration on the enteroinsular axis in horses with insulin dysregulation
Journal of Veterinary Internal Medicine · 2025
DOI: 10.1111/jvim.17256 ↗At a glance
Journal article in Journal of Veterinary Internal Medicine, 2025. Written by Kate L Kemp and 2 co-authors. Institution: School of Veterinary Science, The University of Queensland, 5391 Warrego Hwy, Gatton, Queensland, 4343, Australia. Major MEDLINE topics: Phenylbutazone, Horse Diseases, Cross-Over Studies, Insulin. 33 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Morris Animal Foundation, The University of Queensland Graduate School Research Training Program (RTP) Scholarship and Destination Australia Scholarship: Awarded to Kate L. Kemp.
Abstract (original language)
Background
Phenylbutazone is prescribed for laminitis-associated pain and decreases glucose and insulin responses to an oral glucose test (OGT) in horses with insulin dysregulation (ID). Hypothesis/Objectives Investigate the effect of phenylbutazone administration on the enteroinsular axis in horses. Animals Sixteen horses, including 7 with ID.
Methods
Randomized cross-over study design, with horses assigned to treatment with phenylbutazone (4.4 mg/kg IV q24h) or placebo (5 mL 0.9% saline). On Day 9 of treatment, an OGT was conducted, followed by a 10-day washout period, administration of the alternative treatment, and repetition of the OGT. Glucose-dependent insulinotropic polypeptide (GIP), and active glucagon-like peptide 1 and 2 (aGLP-1 and GLP-2) concentrations were determined by ELISA. The effects of ID status and treatment on peptide concentrations were assessed using t tests and analyses of variance.
Results
Horses with ID had significantly higher maximum GIP concentrations (Cmax) than controls (median, 279.1; interquartile range [IQR], 117.5-319.4 pg/mL vs median, 90.12; IQR, 74.62-116.5 pg/mL; P = .01), but no significant effect of ID was detected on aGLP-1 and GLP-2 concentrations. In horses with ID, phenylbutazone treatment significantly decreased GIP Cmax compared with placebo (168.1 ± 59.26 pg/mL vs 242.8 ± 121.8 pg/mL; P = .04), but no significant effect of phenylbutazone was detected on aGLP-1 and GLP-2 concentrations. Conclusion and Clinical Importance Glucose-dependent insulinotropic polypeptide, aGLP-1 and GLP-2 do not mediate the decrease in glucose and insulin concentrations observed after phenylbutazone administration. Only GIP was repeatedly associated with ID status, calling into question the role of the enteroinsular axis in ID.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- School of Veterinary Science, The University of Queensland, 5391 Warrego Hwy, Gatton, Queensland, 4343, Australia.
- School of Agriculture and Environmental Science, University of Southern Queensland, 487 - 35 West St, Darling Heights, Queensland, 4350, Australia.
- College of Veterinary Medicine, Department of Veterinary Clinical Sciences, Purdue University, 625 Harrison St, West-Lafayette, Indiana, 47909, USA.
ORCID profiles: Kate L Kemp, François-René Bertin
Funding
- Morris Animal Foundation
- The University of Queensland Graduate School Research Training Program (RTP) Scholarship and Destination Australia Scholarship: Awarded to Kate L. Kemp
Cite
APA
Kemp, K. L., Skinner, J. E., & Bertin, F. R. (2025). Effect of phenylbutazone administration on the enteroinsular axis in horses with insulin dysregulation. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.17256
Vancouver
Kemp KL, Skinner JE, Bertin FR. Effect of phenylbutazone administration on the enteroinsular axis in horses with insulin dysregulation. Journal of Veterinary Internal Medicine. 2025. doi:10.1111/jvim.17256
BibTeX
@article{Kemp2025,
author = {Kemp, Kate L and Skinner, Jazmine E and Bertin, François-René},
title = {Effect of phenylbutazone administration on the enteroinsular axis in horses with insulin dysregulation},
journal = {Journal of Veterinary Internal Medicine},
year = {2025},
doi = {10.1111/jvim.17256}
}
EUVIMED